Dr. Reddy's Laboratories and Alvotech are collaborating to develop, manufacture, and commercialize a biosimilar version of ...

Dr. Reddy's Laboratories has partnered with Alvotech to co-develop and commercialize a biosimilar for pembrolizumab (Keytruda ...

Alvotech and Dr. Reddy’s Enter into collaboration to co-develop biosimilar candidate to Keytruda® (pembrolizumab).

Dr. Reddy's Laboratories and Alvotech have partnered to co-develop, manufacture, and commercialize a biosimilar of Keytruda ...

LIC’s shareholding in Dr. Reddy’s Laboratories rose from 5.6% at the end of September 2024 to 6.5% by December 2024, and ...

Dr. Reddy's and Alvotech have partnered to co-develop a biosimilar of Keytruda, Merck's $29.5 billion cancer drug, boosting ...

HSBC upgraded Dr. Reddy’s Laboratories Limited (NYSE:RDY) from Buy to Hold, raising the price target to INR1,445 from ...

Dr. Reddy's and Alvotech collaborate to develop biosimilar to Keytruda, enhancing oncology capabilities and global reach.

Alvotech and Dr Reddy's entered into a collaboration and license agreement to co-develop, manufacture and commercialize a ...

Dr. Reddy's Laboratories Ltd. closed 9.17% short of its 52-week high of 1,420.20 rupees, which the company reached on August ...

Alvotech (ALVO) and Dr. Reddy’s Laboratories (RDY) have entered into a collaboration and license agreement to co-develop, ...

Under the agreement signed between the two companies, Alvotech and Dr. Reddy’s will be jointly responsible for developing and ...